Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label Study of Bevacizumab (AVASTIN) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer

Next Previous
Trial Profile

Open-label Study of Bevacizumab (AVASTIN) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Platinum complexes
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms SAiL
  • Sponsors Roche

Most Recent Events

  • 21 Jan 2022 This trial has been completed in Slovenia, according to European Clinical Trials Database record. (30 Jun 2009)
  • 06 Nov 2019 Results comparing efficacy of first-line bevacizumab-bases therapy in advanced non-squamous, Non Small-Cell Lung Cancer presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
  • 11 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top